Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice

被引：17

作者：

Scheinberg, Morton ^{[1
,2
]}

Castaneda-Hernandez, Gilberto ^{[3
]}

机构：

[1] Clin Res Ctr Hosp AACD, BR-05652000 Sao Paulo, Brazil

[2] Hosp Albert Einstein, BR-05652000 Sao Paulo, Brazil

[3] CINVESTAV, Dept Pharmacol, Mexico City 07360, DF, Mexico

来源：

ARTHRITIS RESEARCH & THERAPY | 2014年 / 16卷 / 06期

关键词：

RHEUMATOID-ARTHRITIS; INNOVATOR INFLIXIMAB; PARALLEL-GROUP; DOUBLE-BLIND; BIOSIMILARS; EFFICACY; DISEASES; THERAPY; SAFETY; EUROPE;

D O I：

10.1186/s13075-014-0501-5

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Biosimilars that were not compared in clinical trials with the compound innovator are not true biosimilars (biocopies) and are associated with risks that the clinical rheumatologist should be aware of before generalized use. This article comments on various aspects surrounding the use of such biocopies in clinical rheumatology.

引用

页数：3

共 17 条

[1] Decreased need of large joint replacement in patients with rheumatoid arthritis in a specialized Brazilian center [J].

Almeida De Piano, Luciana Pereira ;

Golmia, Ricardo Prado ;

Scheinberg, Morton Aaron .

CLINICAL RHEUMATOLOGY, 2011, 30 (04) :549-550

[2] Approval of the first biosimilar antibodies in Europe A major landmark for the biopharmaceutical industry [J].

Beck, Alain ;

Reichert, Janice M. .

MABS, 2013, 5 (05) :621-623

[3] A survey of the use of foreign-purchased medications in a border community emergency department patient population [J].

de Guzman, Grace C. ;

Khaleghi, Murdoc ;

Riffenberg, Robert H. ;

Clark, Richard F. .

JOURNAL OF EMERGENCY MEDICINE, 2007, 33 (02) :213-221

[4] The role of biosimilars in the treatment of rheumatic diseases [J].

Doerner, Thomas ;

Strand, Vibeke ;

Castaneda-Hernandez, Gilberto ;

Ferraccioli, Gianfranco ;

Isaacs, John D. ;

Kvien, Tore K. ;

Martin-Mola, Emilio ;

Mittendorf, Thomas ;

Smolen, Josef S. ;

Burmester, Gerd R. .

ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (03) :322-328

[5]

Federal Commission for the Protection against Sanitary Risk, 2012, COMM HLTH PROF AN RE

[6]

Generics and Biosimilars Initiative (GaBI), NORW STUD HOP INCR B

[7]

da Mota LMH, 2013, REV BRAS REUMATOL, V53, P158, DOI 10.1590/S0482-50042013000200004

[8] Immune-mediated inflammatory diseases (IMIDs) and biologic therapy:: a medical revolution [J].

Kuek, Annabel ;

Hazleman, Brian L. ;

Oestoer, Andrew J. K. .

POSTGRADUATE MEDICAL JOURNAL, 2007, 83 (978) :251-260

[9] Epoetin Biosimilars in Europe: Five Years On [J].

Mikhail, Ashraf ;

Farouk, Mourad .

ADVANCES IN THERAPY, 2013, 30 (01) :28-40

[10] Biosimilars in rheumatology: a view from Latin America [J].

Mysler, Eduardo ;

Scheinberg, Morton .

CLINICAL RHEUMATOLOGY, 2012, 31 (09) :1279-1280

← 1 2 →